Literature DB >> 32852342

Hybrid coronary revascularization: are we there yet?

Maureen McKiernan1, Michael E Halkos.   

Abstract

PURPOSE OF REVIEW: With advances in minimally invasive surgical and percutaneous coronary therapies, hybrid coronary revascularization (HCR) is well positioned to be an ideal strategy for revascularization in selected patients with multivessel coronary artery disease (CAD). The purpose of this review is to highlight recent outcomes and comparative effectiveness studies of HCR. RECENT
FINDINGS: Patients undergoing HCR have comparable outcomes compared with coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The major benefits compared with CABG appear to be related to short-term morbidity and resource utilization. Compared with PCI, HCR may decrease repeat revascularization rates by decreasing reintervention of the left anterior descending coronary artery.
SUMMARY: Although HCR is associated with a significant learning curve, specifically with minimally invasive CABG techniques, the early outcomes remain promising and should be considered as a viable option for revascularization in select patients with multivessel CAD.

Entities:  

Mesh:

Year:  2020        PMID: 32852342     DOI: 10.1097/HCO.0000000000000784

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  2 in total

Review 1.  Comparison of hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: a meta-analysis.

Authors:  Li Yu; Keying Zhu; Nannan Du; Yuexiu Si; Jiali Liang; Ruijing Shen; Bangsheng Chen
Journal:  J Cardiothorac Surg       Date:  2022-06-07       Impact factor: 1.522

2.  One-Stop Hybrid Coronary Revascularization Versus Off-Pump Coronary Artery Bypass Grafting in Patients With Multivessel Coronary Artery Disease.

Authors:  Dongjie Li; Yulin Guo; Yingdi Gao; Xiangguang An; Yan Liu; Song Gu; Xitao Zhang; Jiuchang Zhong; Jie Gao; Pixiong Su
Journal:  Front Cardiovasc Med       Date:  2021-12-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.